• State of Drug Discovery in 2007
• Toxicology Measurement Issues
• Alternative Approaches to Early Tox
• About This Report
• Market Overview

Chapter Two: Pharma Strategies and Toxicology

• Tactics
• Abbott: Developing Their Own Tools
• Bristol-Myers Squibb: Reducing Drug Attrition
• Eli Lilly: Safety, Toxicity, and the FDA
• Glaxo SmithKline: Promoting Productivity
• Johnson & Johnson: Alliances and Biomarkers
• Novartis: Cheminformatics & Model building
• Pfizer: Multiple approaches
• Wyeth: Hitting Their Targets

Chapter Three: In Silico Approaches: Databases and Modeling

• Background
• Databases
• Data Mining and Analysis
• In-Silico Modeling
  • Standard Tests
  • Commercial Modeling Products
    • Advanced Chemistry Development (ACD)
    • Bio-Rad
    • GeneGo
    • Fujitsu Biosciences
    • Gene Logic
    • IDBS
    • Inpharmatica
    • Simulations Plus
  
  
• Predicting Toxicity with QSARs and Expert Modeling Systems
• Government Agency and Public Initiatives
  • EPA’s NCCT
  • FDA
    • ToxCheck
    • ChemBench
  
  
• In-Silico Markets in Early Tox

Chapter Four: In Vitro Assays & Platforms

• Biochemical Assays & Systems
  • Assays
    • BD Biosciences
    • Promega’s
    • Invitrogen
    • Systems
    • Beckman Coulter
    • Tecan
    • Molecular Devices
    • Hamilton
    • NIMBUS Biotechnology
  
  
• Cellular Assays & High-Content Screening (HCS)
  • HCS Platforms
    • Cellomics
    • Beckman
    • GE Biosciences
    • CompuCyte
    • Imstar S.A.
  • Assays
    • Cellomics
    • GE Biosciences
    • Exelixis
    • Caliper
    • Promega
  
  
• Toxicogenomics
  • High Throughput Genomics
  • Gene Logic
  • Gentronix
  • Iconix
  
  
• New Technologies & Approaches
  • ACEA Biosciences
  • Amphioxus Cell Technologies
  • ACEA Biosciences
  • Cellartis AB
  • VistaGen Therapeutics
  • ESA
  • High Throughput Genomics
  • Hurel
  • InvivoSciences LLC
  • Qualyst
  • Solidus Biosciences
  • Others (Cytomyx Ltd, Cyprotex, CreaCell, Neurion, ChanTest)
  
  
• Markets for In Vitro Early Tox Products
  • Biochemical Assays
  • Cellular Assays
  • Instruments and Platforms

Chapter Five: In-Vivo Testing: Animal Models & Human Microdosing

• Animal Models
  • Traditional Animal Models
  • Zebrafish
    • Role in Drug Discovery Testing
    • Applications in Toxicology
    • Charles River Laboratories
    • Daniolabs
    • Phylonix
    • Zygogen
  • Other Animal Models
    • Rat Models—Hepaticus, Inc.
    • Mouse Models—University of North Carolina
    • Caenorhadbitis elegans--Affymetrix
    • Caenorhadbitis elegans-- NemaRx
    • Drosophila—Indiana University
    • Drosophila—Affymetrix
  
  
• Human Microdosing
• Markets for In-Vivo Products

Chapter Six: Service Suppliers

• Customers for Early Tox Services
• Suppliers of In Silico Services
• Suppliers of In Vitro Testing Services
• Product Suppliers That Provide In Vitro Services
• Suppliers of Animal Testing Services
  • Suppliers of Services Using Traditional Animals
  • Suppliers of Services Using Zebrafish
  • Suppliers of Services Using Transgenic Rodents
• Service Supplier Markets for Early Tox

Chapter Seven: Expert Views on Early Tox

• General Questions
  • ADMET has been treated like a single subject. Is there any merit in considering early tox separately from ADME?
  • What are the most important things early tox should tell you?
  • Which potential problems and what organ systems should early tox address?
  • What are the factors that have made early tox so difficult to deal with?
  • In-silico, In-vitro, In-vivo: Which of these three areas hold the most promise?
  • If early tox predictions could be made with better than 75% accuracy, how would this impact drug discovery?
  • What approach(s) do you use in your early tox work?
  • How large is the market for early tox? How fast is it growing?
  
  
• Questions About In silico Approaches
  • Which in-silico models have been most effective predictors?
  • Who are the leading suppliers of models for early tox?
  • Which new models should capture our attention?
  • Which databases are most useful?
  • How important is data sharing between companies (consortiums)?
  
  
• Questions About In vitro Approaches
  • How important are cellular assays and HCS for early tox work?
  • Will they displace traditional biochemical assays for early tox?
  • What is the role of toxicogenomics in early tox?
  • Will chip assays displace microplate assays as the method of choice?
  • What are the hottest new approaches to in-vitro early tox?
  
  
• Questions about In Vivo Approaches
  • Which animal models are most useful in early tox?
  • Will zebrafish assays replace more costly rodent models?
  • What are the advantages and limitations of zebrafish models?
  • What role do you expect human microdosing to play in drug discovery?
  • What impact will microdosing have on early tox?

Chapter Eight: Company Profiles

• Accelrys
  • Company Background
  • Financials
  • Product Lines
  • Products and Approach for Early Tox
  • Approaches to Market
  
  
• ACEA
  • Company Background
  • Technology & Product Description
  • Applications
  • Approaches to Market
  
  
• Albany Molecular Research Inc. (AMRI)
  • Company Focus
  • Financials
  • Chemistry Services
  • ComGenex Acquisition
  • Future Opportunities & Challenges
  
  
• Amphioxus Cell Technologies (Stem Cell Innovations)
  • Company Background
  • Technology
  • Products and Services
  • Approach to Market
  
  
• BD Biosciences
  • Becton Dickenson
  • BD Biosciences
  • Products for Early Tox
  • Plastic Disposables
  • ADME/Tox Products & Services
  • BD Bioimaging Systems
  • Approach to Market
  
  
• Beckman Coulter, Inc.
  • Company Overview
  • Business Areas
  • Financials
  • Biomedical Research, Drug Discovery, ADMET Products
  • Approach to Market
  
  
• Bio-Rad Laboratories
  • Company Description
  • Financials
  • Life Science Research Products
  • Informatics / Sadtler Group
  • KnowItAll Cheminformatics System
  
  
• Caliper Life Sciences (formerly Zymark)
  • Background & History
  • Financials
  • Instrument Systems for Automation
  • Caliper Discovery Alliances & Services (CDAS)
  
  
• Cambridge Cell Networks
  • Background
  • Products & Services
  • The Buzz on ToxWiz
  
  
• CeeTox
  • Background & Focus
  • Technology and Toxicity Testing Services
  • Early Tox Services
  • Future
  
  
• Cellartis
  • Background
  • Technology & Products
  
  
• Cellomics
  • Company History
  
  
• HCS Products
  • Cellomics Alliances and Future
  
  
• Charles River Laboratories
  • Overview & Focus
  • Financials
  • Research Models and Services
  • PreClinical Services
  • Future Directions
  
  
• CompuCyte
  • Company Focus
  • CompuCyte Products
  • LSC Technology and Use in Drug Discovery
  • iCyte Applications in Toxicology
  
  
• Elsevier MDL
  • Company History & Focus
  • Drug Discovery Product Lines
  • Collaborations
  
  
• GE Healthcare Bio-Sciences (formerly Amersham Biosciences)
  • About GE Healthcare
  • About GE Healthcare Bio-Sciences
  • Products for Early Tox
  • LEADseeker
  • IN Cell Platforms
  • Reagents & Early Tox Applications
  • Approach to Market
  
  
• Gene Logic
  • Background & History
  • Gene Logic Re-Invented
  • Financials
  • Genomics & Toxicogenomics Products & Services
  • Future
  
  
• High Throughput Genomics
  • Company Focus
  • Technology
  • Products & Services
  • Applications
  
  
• Hurel Corporation
  • Company Focus
  • Technology and Applications
  
  
• Iconix Biosciences
  • Company History & Focus
  • Technology & Products
  • Partnerships & Alliances
  • Future Opportunities
  
  
• ID Business Solutions Ltd. (IDBS)
  • Background & History
  • Areas of Focus
  • Drug Discovery Products
  • Approach to the Market
  
  
• Invitrogen
  • Background & History
  • Areas of Focus
  • Financials
  • Invitrogen Contract Services & BioReliance
  • Assays & Reagents for Drug Discovery
  • Approach to the Market
  
  
• Phylonix
  • Company Background
  • Phylonix Services
  
  
• PreClinOmics
  • Company History & Focus
  • Technology, Products & Services
  • Benefits & Collaborations
  
  
• Promega
  • Company Focus
  • Product Lines and Early Tox
  • Applications Support
  • Approach to Market
  
  
• Qualyst
  • Background & History
  • B-Clear System Technology
  • Commercial Products & Services
  
  
• Simulations Plus
  • Background & History
  • Financials
  • ADME Prediction Software
  
  
• Solidus Biosciences
  • Background
  • Technology
  • Future Plans
  
  
• Xceleron
  • Background
  • Technology & Rationale
  • Applications & Services
  • Marketing & Future
  
  
• Zygogen
  • Company Background
  • Technology
  • Applications, Advantages & Products
  • Affililiations & Expansion

List of Exhibits
Chapter One: Executive SummarY

• Figure 1-1: Market Summary: Early Toxicology Market 2006-2010
• Figure 1-2: Distribution of Early Tox Market by Area (In Silico Products, In Vitro Products, In VivoProducts, Early Tox Services) 2006
• Table 1-1: Leading Competitors by Market Area 2006

Chapter Three: In Silico Approaches: Databases and Modeling

• Table 3-1: Summary of Pros and Cons of In-Silico Modeling
• Table 3-2: Toxicity Software Products and Suppliers
• Table 3-3: Market Size of In-Silico Products for Early Toxicology by Product Area (Databases, Data Mining Tools, Modeling) 2006, 2010
• Table 3-4: Average Annual Growth of In-Silico Products by Product Area (Databases, Data Mining Tools, Modeling) 2006-2010
• Table 3-5: Leading Competitors of In-Silico Products by Product Area (Databases, Data Mining Tools, Modeling) 2006

Chapter Four: In Vitro Assays & Platforms

• Table 4-1: Market Size of In Vitro Products for Early Toxicology by Product Area (Biochemical Assays, Cellular Assays, Instruments & Platforms) 2006, 2010
• Table 4-2: Average Annual Growth of In Vitro Products by Product Area (Biochemical Assays, Cellular Assays, Instruments & Platforms) 2006-2010
• Table 4-3: Leading Competitors of In Vitro Products by Product Area (Biochemical Assays, Cellular Assays, Instruments & Platforms) 2006

Chapter Five: In-Vivo Testing: Animal Models & Human Microdosing

• Table 5-1: Market Size of In Vivo Products for Early Toxicology by Product Area (Mice & Traditional Animals, Zebrafish Models, Other Animals, Human Microdosing) 2006, 2010
• Table 5-2: Average Annual Growth of In Vitro Products by Product Area (Mice & Traditional Animals, Zebrafish Models, Other Animals, Human Microdosing) 2006-2010
• Table 5-3: Leading Competitors of In Vitro Products by Product Area (Mice & Traditional Animals, Zebrafish Models, Other Animals, Human Microdosing) 2006

Chapter Six: Service Suppliers

• Table 6-1: Market Size of Services for Early Toxicology by Service Area (In Silico, In Vitro, In Vivo) 2006, 2010
• Table 6-2: Average Annual Growth of Services for Early Toxicology by Service Area (In Silico, In Vitro, In Vivo) 2006-2010
• Table 6-3: Leading Competitors in Services for Early Toxicology by Service Area (In Silico, In Vitro, In Vivo) 2006

Chapter Eight: Company Profiles

• Figure 8-1: Demographics of Companies Profiled (Name, Location, Affiliation, Revenues, Product/Service Area)